Key 2018/2019 Developments in Lymphoma and Thrombosis/Anticoagulation — Medical and Surgical Oncology Lecture

Stephan Moll, MD

Professor of Medicine
Hemophilia and Thrombosis Center
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Anne W. Beaven, MD

Associate Professor of Medicine
Director, Lymphoma Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Each year, the American Society of Hematology (ASH) hosts a conference highlighting some of the latest hematologic oncology research. Join us as our speakers highlight some of the top presentations on Non-Malignant Hematology and Lymphoma from this year’s ASH conference.

Lecture Objectives:

• Discuss the risk/benefit of prophylactic dose apixaban or rivaroxaban in ambulatory cancer patients starting chemotherapy, who have never had a DVT or PE.
• Decide which anticoagulant is best to use in the severely obese patient and the patient who has had bariatric surgery who has an indication for full dose anticoagulation.
• Describe the use of brentuximab vedotin as front line treatment of patients with CD30+ Peripheral T Cell Lymphoma.
• Recognize that a short course of RCHOP chemotherapy alone may be effective in treatment of young patients with low risk DLBCL.